Skip to content

Trial Summary

A Phase 1b open-label, multicentre dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumours

Acronym:

MT-5111

ACTRN/NCT /ethics:

NCT04029922

Scientific title:

Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)

Sponsor / Cooperative group:

Molecular Templates, Inc.

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-11-12
Anticipated End Date2025-05-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Emailadmin@cancerresearchsa.com.au
Phone08 8359 2565
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting